Press Release | ERDERA Clinical Trial Call

1:1
ERDERA launches Clinical Trial Call 2026 to advance early‑phase clinical trials for rare diseases

ERDERA has opened its Clinical Trial Call 2026, a funding opportunity for multinational early-phase interventional clinical trials in rare diseases.

The call supports sponsor-led Phase I, Phase I/II and Phase II trials of medicinal products designed to generate robust clinical evidence, strengthen regulatory readiness and improve trial feasibility across countries.

Up to €30 million is dedicated to the call, with individual project budgets broadly expected in the range of €1 million to €5 million.

You might also be interested in

This 2026 country report outlines the policy, research, care and support landscape for rare diseases in Poland.
Held in Riga on 9–10 June, the workshop brought National Mirror Group experts, researchers, clinicians and policymakers together to exchange practical lessons on how national rare disease registries can better support research and alignment across countries.
ERDERA (the European Rare Diseases Research Alliance) has opened its Clinical Trial Call to support multinational early-phase clinical trials in rare diseases. The call will fund studies designed to generate robust clinical evidence, strengthen regulatory readiness and make rare disease trials more feasible across countries.
Call text draft setting out rules, eligibility and staged application process for the ERDERA Clinical Trial Call 2026.